<DOC>
	<DOCNO>NCT01538732</DOCNO>
	<brief_summary>This single center , prospective , open label , single arm , investigator initiate pilot study investigate effect alitretinoin severe lichen planus mucosal manifestation . The target population comprise patient MLP least 3 month , without LP lesion area skin , refractory topical therapy standard skin care , otherwise good health . Patients recruit outpatient clinic dermatology department , University hospital Zurich.The plan duration study 2 year . A total 20 patient include . Patients meet enrolment criterion receive 30mg alitretinoin , give orally gelatin capsule , daily 24 week . Dose interruption permit response adverse effect , consistent use retinoids product label . Most clinical evaluation perform every 4 week . A safety follow-up visit plan 4 week end treatment . Further follow-up visit conduct 16 24 week end treatment patient meet primary endpoint - Trial medicinal product</brief_summary>
	<brief_title>Lichen Planus Mucosae USZ , Efficacy Oral Alitretinoin</brief_title>
	<detailed_description />
	<mesh_term>Lichen Planus</mesh_term>
	<mesh_term>Alitretinoin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Inclusion criterion Aged 18 75 year MLP least 3 month Disease activity accord Escudier score 10 point great erosive lesion score Refractory standard topical therapy Consensus 2 week washout period topical steroid start study treatment Exclusion criterion Unable comply requirement study Pregnant lactate woman Female patient childbearing potential use commit use two effective form contraception simultaneously supervision investigator gynecologist Active hepatitis and/or vaccination hepatitis A/B last 4 week Adequate control disease standard topical therapy standard topical corticosteroid therapy Known hypersensitivity retinoids vitamin A derivative , study medication component Patients treat follow treatment 4 week start study treatment : 1. systemic drug : corticosteroid , immunosuppressant , methotrexate 2. phototherapy Treatment systemic topical retinoids within 1 year 1 month , respectively , start study treatment treatment systemic retinoids treatment MLP time coexistence serious medical condition , opinion investigator , may interfere safety patient , include 1. hepatic insufficiency ( alanine aminotransferase /or aspartate aminotransferase value &gt; 2.5 x ULN ) 2. severe renal failure 3. uncontrolled hypertriglyceridemia ( triglyceride &gt; 150 % upper limit normal ) , 4. uncontrolled hypercholesterolemia ( cholesterol low density lipoprotein ( LDL ) cholesterol value &gt; 1.5 x ULN 5 . Patients cardiovascular risk factor would exclude start dose 30 mg alitretinoin 6 . Uncontrolled hypothyroidism 7 . Hypervitaminosis A 8 . Active major psychiatric disorder include depression suicidal ideation Concomitant medication systemic tetracycline , CYP3A4 inhibitor ketoconazole , Vitamin A St. John 's Wort within 1 week , receive systemic itraconazole within 2 week , start study treatment Trial participation within 2 month start study treatment ( 3 month biologics )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>